HSP90 as a novel molecular target in non-small-cell lung cancer
Khashayar Esfahani, Victor Cohen Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada Abstract: Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the land...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c825e459e0d84d2aafce3734f4eeb073 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Khashayar Esfahani, Victor Cohen Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada Abstract: Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the landscape for the treatment of non-small-cell lung cancer (NSCLC). Targeted therapies against epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have now been approved by the Food and Drug Administration as part of the standard first-line treatment of NSCLC. Despite good initial responses, most patients develop resistance within 8–12 months and have disease progression. Keywords: non-small-cell lung cancer, driver mutations, targeted therapy, heat shock protein 90 (HSP90) |
|---|